Corporate Banner
Satellite Banner
Technology
Networks
Scientific Communities
 
Become a Member | Sign in
Home>News>This Article
  News
Return

World Awaits Biosimilars Boom

Published: Thursday, October 04, 2012
Last Updated: Wednesday, October 03, 2012
Bookmark and Share
Biosimilars set to take a sizable chunk of the global biopharmaceuticals market by 2020, new report predicts.

With an introduction to the US set for 2014, and the realization of massive potential in the emerging markets of Asia, biosimilars are set to take a sizable chunk of the global biopharmaceuticals market by 2020, predicts a new report by global business intelligence firm GBI Research.

According to the latest study, the massive potential for pharmaceuticals in the US means that the country’s biosimilars market could be valued at $9 billion by the end of the decade, despite the fact that they will only enter the market in 2014.

Similarly, the activities of major pharmaceutical companies such as Dr. Reddy’s will see the Indian biosimilars sector treble in value in just five years, from $482m in 2011 to $1.4 billion by 2016.

GBI Research notes that ‘pharmerging’ countries across Asia have attracted the interest of big biopharmaceutical players, with lenient regulations and tax incentives available during the initial industrial phase.

Already more than 20 biosimilar companies operate in India, with approximately 55 products in the market, while the State Food and Drug Administration (SFDA) in China had approved 40 biopharmaceutical products up until December 2011 - the majority of which were biosimilars.

South Korea has also on record as a committed industry advocate, with the Korean government announcing a target of achieving 22% of the global market share for biosimilars by 2015.

The global biopharmaceutical market was valued at $138 billion in 2011 and is expected to grow to over $320 billion by 2020. Roche dominated the global production of biopharmaceuticals last year, manufacturing 25% of the total.

Johnson & Johnson was second with a share of 8.8%, while Boehringer Ingleheim was the third largest manufacturer in the sector, holding an 8.5% share.


Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,500+ scientific posters on ePosters
  • More Than 3,800+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Global Biosimilars Market Value Could Hit $55 Billion by 2020, says GBI Research
Promising pipeline in active development and government efforts to reduce healthcare spending.
Thursday, July 02, 2015
Big Pharma Embraces Biologics
Increased uptake of biologics boosts API revenues and promote growth in the biopharmaceutical market.
Friday, November 30, 2012
Biologics and Stem Cell Research Boost the Cell Culture Market
Cell culture market expected to grow at a CAGR of 9.3% between 2011 and 2018.
Thursday, November 15, 2012
Outsourcing in Asia to Shrink Japan’s Revenue Share
Pharma’s interest in outsourcing, combined with rising industrialization in India and China, will mark a drop in Japan’s share of the continent’s revenue.
Tuesday, November 06, 2012
‘Tis the Season to Be Sniffly - Seasonal Influenza Boosts Vaccines Market
Acute viral respiratory infection influenza, or flu, strikes every winter, and several nations are preparing to tackle this illness through dedicated healthcare schemes, states a new report by healthcare experts GBI Research.
Monday, October 22, 2012
Innovation May Mean Collaborations for Drug Development in Future
Research collaborations and shared data will mark a change in the fiercely competitive pharmaceutical world, states a new report by healthcare experts GBI Research.
Wednesday, September 26, 2012
Struggling Pharma Companies to Outsource Clinical Trial Research
Falling revenue in some healthcare sectors means companies are making huge efforts to reduce R&D expenditure and increase profitability.
Monday, April 23, 2012
Cost of Antivirals for HIV/AIDS Set to Increase
Antiviral drugs become expensive due to the launch of new combination therapies.
Friday, April 06, 2012
Scientific News
Health Risks of Saturated Fats Aggravated by Immune Response
Research shows that the presence of saturated fats resulted in monocytes migrating into the tissues of vital organs.
Changing the Biological Data Visualisation World
Scientists at TGAC, alongside European partners, have created a cutting-edge, open source community for the life sciences.
NIH Study Finds Calorie Restriction Lowers Some Risk Factors for Age-Related Diseases
Two-year trial did not produce expected metabolic changes, but influenced other life span markers.
Immunotherapy Agent Benefits Patients with Drug-Resistant Multiple Myeloma in First Human Trial
Daratumumab proved generally safe in patients, even at the highest doses.
Low-level Arsenic Exposure Before Birth Associated with Early Puberty in Female Mice
Study examine whether low-dose arsenic exposure could have similar health outcomes in humans.
Inciting an Immune Attack On Cancer Cells
A new minimally invasive vaccine that combines cancer cells and immune-enhancing factors could be used clinically to launch a destructive attack on tumors.
‘Mutation-Tracking’ Blood Test for Breast Cancer
Scientists have developed a blood test for breast cancer able to identify which patients will suffer a relapse after treatment, months before tumours are visible on hospital scans.
Cellular Contamination Pathway for Heavy Elements Identified
Berkeley Lab scientists find that an iron-binding protein can transport actinides into cells.
Intensity of Desert Storms May Affect Ocean Phytoplankton
MIT study finds phytoplankton are extremely sensitive to changing levels of desert dust.
Common ‘Heart Attack’ Blood Test May Predict Future Hypertension
Small rises in troponin levels may have value as markers for subclinical heart damage and high blood pressure.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,800+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FREE!